D-dimers

Art. No.

A076

Synonym

DD-XLink-mab

Background info

After proteolytic activation by thrombin, FXIIIa modifies the soft fibrin clot and thereby introducing covalent bonds. First, cross-linking between abutting -chains of fibrin is catalyzed and subsequently 2-antiplasmin is incorporated to further increase the resistance against fibrinolysis. Plasmin catalyses the retarded clot dissolution and the release of crosslinked fibrin degradation products (xFDPs / D-dimer) (figure 1). Monoclonal “D-dimer” antibodies (e.g. DD-3B6/22) are commercially available and are used in In Vitro Diagnostics (IVD) to exclude thromboembolic events. However, these monoclonals do not detect the crosslink itself but address a portion of polypeptides within the D-domain after plasmin degradation that are conformationally reactive. Zedira scientists developed a monoclonal antibody which directly recognizes the crosslinked fibrin neoepitope (DD-XLink-mab) (figure 2).

Host

Mouse

Isotype

IgG2b κ

Immunogen

Human fibrin peptides cross-linked with plasma factor XIIIa.

Specificity

Specific for clot derived xFDPs (crosslinked Fibrin Degradation Products) Minor reactivity with fibrinogen degradation products (FDPs) cannot be excluded (compare to ELISA data in figure 3).

Appearance

liquid

Formulation

The antibody is stored in PBS, 150 mM NaCl (pH 7.4), 0.02% sodium azide

Working dilutions

Optimal dilutions should be determined by the end user. E. g. for Western-Blotting: 1 / 3,000 to 1 / 10,000 should be suitable

Storage

Store at 2 – 8 °C

Note

INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Related Products

A079: Biotin-DD-XLink-mab